{"id":4720,"date":"2021-03-11T19:25:55","date_gmt":"2021-03-12T00:25:55","guid":{"rendered":"https:\/\/ccna-ccnv.ca\/ccna_publication\/type-2-diabetes-as-a-determinant-of-parkinsons-disease-risk-and-progression-2\/"},"modified":"2024-12-03T14:57:28","modified_gmt":"2024-12-03T19:57:28","slug":"type-2-diabetes-as-a-determinant-of-parkinsons-disease-risk-and-progression-2","status":"publish","type":"ccna_publication","link":"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/type-2-diabetes-as-a-determinant-of-parkinsons-disease-risk-and-progression-2\/","title":{"rendered":"Type 2 Diabetes as a Determinant of Parkinson’s Disease Risk and Progression"},"content":{"rendered":"

Abstract<\/h2>\n
\n
\n

Background<\/h3>\n

Type 2 diabetes (T2DM) and Parkinson’s disease (PD) are prevalent diseases that affect an aging population. Previous systematic reviews and meta\u2010analyses have explored the relationship between diabetes and the risk of PD, but the results have been conflicting.<\/p>\n<\/section>\n

\n

Objective<\/h3>\n

The objective was to investigate T2DM as a determinant of PD through a meta\u2010analysis of observational and genetic summary data.<\/p>\n<\/section>\n

\n

Methods<\/h3>\n

A systematic review and meta\u2010analysis of observational studies was undertaken by searching 6 databases. We selected the highest\u2010quality studies investigating the association of T2DM with PD risk and progression. We then used Mendelian randomization (MR) to investigate the causal effects of genetic liability toward T2DM on PD risk and progression, using summary data derived from genome\u2010wide association studies.<\/p>\n<\/section>\n

\n

Results<\/h3>\n

In the observational part of the study, pooled effect estimates showed that T2DM was associated with an increased risk of PD (odds ratio [OR] 1.21, 95% confidence interval [CI] 1.07\u20131.36), and there was some evidence that T2DM was associated with faster progression of motor symptoms (standardized mean difference [SMD] 0.55, 95% CI 0.39\u20130.72) and cognitive decline (SMD \u22120.92, 95% CI \u22121.50 to \u22120.34). Using MR, we found supportive evidence for a causal effect of diabetes on PD risk (inverse\u2010variance weighted method [IVW] OR 1.08, 95% CI 1.02\u20131.14;\u00a0P<\/i>\u00a0=\u20090.010) and some evidence of an effect on motor progression (IVW OR 1.10, 95% CI 1.01\u20131.20;\u00a0P<\/i>\u00a0=\u20090.032) but not on cognitive progression.<\/p>\n<\/section>\n

\n

Conclusions<\/h3>\n

Using meta\u2010analyses of traditional observational studies and genetic data, we observed convincing evidence for an effect of T2DM on PD risk and new evidence to support a role in PD progression. \u00a9 2021 The Authors.\u00a0Movement Disorders<\/i>\u00a0published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society<\/p>\n<\/section>\n<\/div>\n","protected":false},"author":19,"featured_media":0,"template":"","meta":{"_acf_changed":false},"studies-relation":[],"class_list":["post-4720","ccna_publication","type-ccna_publication","status-publish","hentry"],"acf":[],"yoast_head":"\nType 2 Diabetes as a Determinant of Parkinson's Disease Risk and Progression - CCNA - CCNV<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/type-2-diabetes-as-a-determinant-of-parkinsons-disease-risk-and-progression-2\/\" \/>\n<meta property=\"og:locale\" content=\"fr_CA\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Type 2 Diabetes as a Determinant of Parkinson's Disease Risk and Progression - CCNA - CCNV\" \/>\n<meta property=\"og:description\" content=\"Abstract Background Type 2 diabetes (T2DM) and Parkinson’s disease (PD) ...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/type-2-diabetes-as-a-determinant-of-parkinsons-disease-risk-and-progression-2\/\" \/>\n<meta property=\"og:site_name\" content=\"CCNA - CCNV\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-03T19:57:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ccna-ccnv.ca\/wp-content\/uploads\/2025\/01\/CCNA.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Estimation du temps de lecture\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/type-2-diabetes-as-a-determinant-of-parkinsons-disease-risk-and-progression-2\/\",\"url\":\"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/type-2-diabetes-as-a-determinant-of-parkinsons-disease-risk-and-progression-2\/\",\"name\":\"Type 2 Diabetes as a Determinant of Parkinson's Disease Risk and Progression - CCNA - CCNV\",\"isPartOf\":{\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/#website\"},\"datePublished\":\"2021-03-12T00:25:55+00:00\",\"dateModified\":\"2024-12-03T19:57:28+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/type-2-diabetes-as-a-determinant-of-parkinsons-disease-risk-and-progression-2\/#breadcrumb\"},\"inLanguage\":\"fr-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/type-2-diabetes-as-a-determinant-of-parkinsons-disease-risk-and-progression-2\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/type-2-diabetes-as-a-determinant-of-parkinsons-disease-risk-and-progression-2\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ccna-ccnv.ca\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Type 2 Diabetes as a Determinant of Parkinson’s Disease Risk and Progression\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/#website\",\"url\":\"https:\/\/ccna-ccnv.ca\/fr\/\",\"name\":\"Canadian Consortium on Neurodegeneration in Aging\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/#organization\"},\"alternateName\":\"CCNA - CCNV\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ccna-ccnv.ca\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/#organization\",\"name\":\"Canadian Consortium on Neurodegeneration in Aging\",\"alternateName\":\"CCNA - CCNV\",\"url\":\"https:\/\/ccna-ccnv.ca\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ccna-ccnv.ca\/wp-content\/uploads\/2025\/01\/ccna-logo-on-white-background.jpg\",\"contentUrl\":\"https:\/\/ccna-ccnv.ca\/wp-content\/uploads\/2025\/01\/ccna-logo-on-white-background.jpg\",\"width\":696,\"height\":696,\"caption\":\"Canadian Consortium on Neurodegeneration in Aging\"},\"image\":{\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Type 2 Diabetes as a Determinant of Parkinson's Disease Risk and Progression - CCNA - CCNV","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/type-2-diabetes-as-a-determinant-of-parkinsons-disease-risk-and-progression-2\/","og_locale":"fr_CA","og_type":"article","og_title":"Type 2 Diabetes as a Determinant of Parkinson's Disease Risk and Progression - CCNA - CCNV","og_description":"Abstract Background Type 2 diabetes (T2DM) and Parkinson’s disease (PD) ...","og_url":"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/type-2-diabetes-as-a-determinant-of-parkinsons-disease-risk-and-progression-2\/","og_site_name":"CCNA - CCNV","article_modified_time":"2024-12-03T19:57:28+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/ccna-ccnv.ca\/wp-content\/uploads\/2025\/01\/CCNA.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Estimation du temps de lecture":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/type-2-diabetes-as-a-determinant-of-parkinsons-disease-risk-and-progression-2\/","url":"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/type-2-diabetes-as-a-determinant-of-parkinsons-disease-risk-and-progression-2\/","name":"Type 2 Diabetes as a Determinant of Parkinson's Disease Risk and Progression - CCNA - CCNV","isPartOf":{"@id":"https:\/\/ccna-ccnv.ca\/fr\/#website"},"datePublished":"2021-03-12T00:25:55+00:00","dateModified":"2024-12-03T19:57:28+00:00","breadcrumb":{"@id":"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/type-2-diabetes-as-a-determinant-of-parkinsons-disease-risk-and-progression-2\/#breadcrumb"},"inLanguage":"fr-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/type-2-diabetes-as-a-determinant-of-parkinsons-disease-risk-and-progression-2\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/type-2-diabetes-as-a-determinant-of-parkinsons-disease-risk-and-progression-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ccna-ccnv.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"Type 2 Diabetes as a Determinant of Parkinson’s Disease Risk and Progression"}]},{"@type":"WebSite","@id":"https:\/\/ccna-ccnv.ca\/fr\/#website","url":"https:\/\/ccna-ccnv.ca\/fr\/","name":"Canadian Consortium on Neurodegeneration in Aging","description":"","publisher":{"@id":"https:\/\/ccna-ccnv.ca\/fr\/#organization"},"alternateName":"CCNA - CCNV","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ccna-ccnv.ca\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-CA"},{"@type":"Organization","@id":"https:\/\/ccna-ccnv.ca\/fr\/#organization","name":"Canadian Consortium on Neurodegeneration in Aging","alternateName":"CCNA - CCNV","url":"https:\/\/ccna-ccnv.ca\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/ccna-ccnv.ca\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/ccna-ccnv.ca\/wp-content\/uploads\/2025\/01\/ccna-logo-on-white-background.jpg","contentUrl":"https:\/\/ccna-ccnv.ca\/wp-content\/uploads\/2025\/01\/ccna-logo-on-white-background.jpg","width":696,"height":696,"caption":"Canadian Consortium on Neurodegeneration in Aging"},"image":{"@id":"https:\/\/ccna-ccnv.ca\/fr\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/ccna-ccnv.ca\/fr\/wp-json\/wp\/v2\/ccna_publication\/4720","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ccna-ccnv.ca\/fr\/wp-json\/wp\/v2\/ccna_publication"}],"about":[{"href":"https:\/\/ccna-ccnv.ca\/fr\/wp-json\/wp\/v2\/types\/ccna_publication"}],"author":[{"embeddable":true,"href":"https:\/\/ccna-ccnv.ca\/fr\/wp-json\/wp\/v2\/users\/19"}],"wp:attachment":[{"href":"https:\/\/ccna-ccnv.ca\/fr\/wp-json\/wp\/v2\/media?parent=4720"}],"wp:term":[{"taxonomy":"studies-relation","embeddable":true,"href":"https:\/\/ccna-ccnv.ca\/fr\/wp-json\/wp\/v2\/studies-relation?post=4720"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}